Ind-Swift Laboratories Limited
Equibles does not estimate personal net worth.
Pardeep Verma has spoken on 1 earnings call across 1 company, most recently for Ind-Swift Laboratories Limited on August 17, 2026. Ind-Swift Laboratories Limited is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
“It continues to be a molecule with a large and growing addressable market globally. Agitabine and Atorva statins saw the sharpest growth in the portfolio with year-on-year growth of 246.97%, more than tripling to 80.78 crore in FY26 from 23.28 crore in FY25.”
Ind-Swift Laboratories Limited
Transcript header (unverified)
Ind-Swift Laboratories Limited
Drug Manufacturers - Specialty & Generic · Healthcare
Earnings Call for the Quarter Ended June 30, 2026
Ind-Swift Laboratories Limited
